The identification of the bioactive small molecules isolated from phenotypic screens plays a key role in drug discovery. Creative Biolabs is a preclinical pharmaceutical company focused on supporting drug and biomarker discovery with its unique expertise and innovative technologies. We provide target deconvolution services that enable the identification of small molecule drug targets, target engagement markers, molecular mechanisms of action and drug response biomarkers.
Target discovery and validation is a crucial step in drug discovery. The phenotypic-based screening approach to drug discovery is an efficient strategy to identify promising small molecule hits. One major challenge for progressing hits from phenotypic screens to mature lead compounds is the identification of the protein target. Therefore, the process of identifying the molecular targets of active hits, also known as target deconvolution, is an essential step for understanding the compound mechanism of action and further optimizing compounds of interest. As shown in Fig.1, the diagram illustrates that the early stage of drug discovery is aimed at identifying targets and leader molecules. In the phenotypic-based approach, lead molecules are obtained and then subjected to target deconvolution to identify molecular targets.
Fig.1 Phenotype-based drug discovery.
Target deconvolution can be achieved by numerous methods including affinity chromatography, expression-cloning, protein microarray, gene/protein expression profiling, and so on. With abundant experience and a professional team of experts in target deconvolution, Creative Biolabs provides innovative services for drug discovery and protein quantification using cutting edge technology. We strive to be the world's leading drug discovery company that provides the best solutions to support researchers in their drug discovery needs.
Creative Biolabs can help you advance medical research and speeds up drug discovery by providing:
Our advanced target deconvolution technologies provide fast, accurate, and effective solutions for discovering the human cell surface and secreted protein targets of antibodies, proteins, viruses, and small molecules. We produce low false-positive rates to ensure that months or even years of research are not wasted chasing dead ends when validating potential target hits. Creative Biolabs' target deconvolution typically results in one or two repeatable hits that are specific to the test molecule such as proteins, antibodies, and small molecules. This enables our global pharmaceutical customers to:
Target deconvolution is a long process that takes a lot of time and money. Don't waste resources on the wrong candidate. We offer a comprehensive range of solutions including the design of your project, the chemical derivatization of your molecule, target screening and identification, and the delivery of fully analyzed results by our dedicated scientists. For any questions about our drug discovery service, please contact us directly.
For Research Use Only.
